

Cabergoline

Health Canada approved products¹:

DIN	Product Name	Strength	Form	Wholesale Cost/Tablet*
02301407	Co-cabergoline	cabergoline 0.5 mg	Oral tablet	\$10.5235
02242471	Dostinex	cabergoline 0.5 mg	Oral tablet	\$14.0200

* McKesson catalogue

Health Canada indications for cabergoline²:

- **Treatment of hyperprolactinemic disorders**, either idiopathic or due to pituitary adenomas.
- **Prevention of the onset of physiological lactation** in the puerperium for clearly defined medical reasons.

Options for treatment of hyperprolactinemia^{3,4}:

- Bromocriptine 2.5 mg oral tablet
 - Pooled analysis of 39 noncomparative studies – resolution of visual field defects in about 67 %, amenorrhea in about 78 %, infertility in about 53 %, galactorrhea in about 86%; reduction in tumour size in about 62 %; improvement in sexual function in about 67%.
 - Dosing
 - Adults
 - initial dose 1.25-2.5 mg/day orally
 - increase by 2.5 mg every 2-7 days based on serum prolactin
 - usual dose range 2.5-15 mg/day
 - Children ≥ 11 years old
 - initial dose 1.25-2.5 mg/day orally
 - increase as tolerated until therapeutic response achieved
 - usual dose range 2.5-10 mg/day
 - Common adverse effects include headache, fatigue, dizziness, nausea, and other gastrointestinal symptoms.
 - Symptomatic hypotension may occur during first few days of treatment.
 - Less effective and less well tolerated than cabergoline.⁵
- Quinagolide (Norprolac) 75 mcg, 150 mcg oral tablets
 - Normalized prolactin levels in 50% to 100% of patients with idiopathic hyperprolactinemia or hyperprolactinemia associated with microprolactinoma, and in 40% to 70% of those with macroprolactinoma. Galactorrhea subsided in all patients treated, with restoration of menses in most. Tumor shrinkage evident in 80% to 100% of macroprolactinoma patients.
 - Dosing in adults
 - initial dose 25 mcg/day
 - increase by 25 mcg every 3 days up to 75 mcg/day
 - usual dose range 75-150 mcg/day, maximum 600 mcg/day
 - Administer once daily at bedtime with a snack.
 - The most commonly observed adverse events (>10%) reported during clinical trials were: nausea, vomiting, headache, dizziness and fatigue.
 - Small comparison studies suggest quinagolide may be somewhat less effective than cabergoline.

Options for lactation suppression:^{7,8}

- Breast binders and avoid nipple stimulation for breast engorgement in women who are not breastfeeding. (Data limited and inconclusive)
- No agents other than cabergoline are officially indicated for lactation suppression.
- **Bromocriptine**
 - May suppress postpartum lactation in women who have not breastfed or expressed breast milk.
 - 2.5 mg twice daily for 14 days equivalent to oral cabergoline 1 milligram (mg) administered once within 27 hours of delivery
 - Indication for this purpose was withdrawn because of serious side effects – hypertension, seizures, and cerebrovascular accidents, severe post-partum psychosis.
- **Quinagolide**
 - Very little data on efficacy and safety for this purpose. In a small open, randomized study (n=30) quinagolide once daily (50 mcg day1, 75 mcg days 2 to 14, 50 mcg to day 21) was comparable in efficacy and tolerability to bromocriptine (2.5 mg once or twice daily) in the prevention of lactation in postpartum women.⁹

Prepared by Karen Jensen, medSask medication information consultant.

June 25, 2014

References:

1. Drug Product Database. Health Canada. Available at <http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp>.
2. Co Cabergoline. Product monograph. Available at <http://webprod5.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng>.
3. Hyperprolactinemia. In Dynamed database online. Available at <https://dynamed.ebscohost.com/>. (Log-in and registration required.) Accessed June 25, 2014.
4. Synder P. Treatment of hyperprolactinemia due to lactotroph adenoma and other causes. In UpToDate database online. Available at www.uptodate.com. (Log-in and registration required.) Accessed June 25, 2014.
5. Want A, Mullan R et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012 Jul 24;1:33.
6. Mann WA. Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach. Eur J Clin Invest 2011 Mar;41(3):334-42.
7. Berens P. Overview of postpartum care. In UpToDate database online. Available at www.uptodate.com. (Log-in and registration required.) Accessed June 25, 2014.
8. Oladapo OT, Fawole B. Treatments for suppression of lactation. Cochrane Database Syst Rev 2012; 9:CD005937.
9. Quinagolide. In: *DRUGDEX System* (Micromedex 2.0). Greenwood Village, CO: Truven Health Analytics; c1974-2014. Available at <http://www.micromedexsolutions.com/micromedex2>. (Log-in and registration required.) Accessed June 25, 2014.